Thermo Fisher Scientific MAGE-1 (Target for Cancer Immunotherapy) Monoclonal Antibody (MZ2E/838)

Applications

Tested Dilution

Publications

Immunohistochemistry (Paraffin) (IHC (P))

Assay-dependent

-

Immunohistochemistry (PFA fixed) (IHC (PFA))

1-2 µg/mL

-

Immunocytochemistry (ICC/IF)

1-2 µg/mL

-

Flow Cytometry (Flow)

1-2 µg/10^6 cells

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Mouse / IgG1, kappa

Class

Monoclonal

Type

Antibody

Clone

MZ2E/838

Immunogen

Recombinant human MAGEA1 protein

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

200 µg/mL

Purification

Protein A/G

Storage buffer

PBS, pH 7.4, with 0.05% BSA

Contains

0.05% sodium azide

Storage conditions

4° C, do not freeze

Shipping conditions

Ambient (domestic); Wet ice (international)

Target Information

Human malignant neoplasms carry rejection antigens that are recognized by the patients` autologous, tumor directed and specific, cytolytic, CD8+ T lymphocyte clones (CTL). An important group of antigens is coded by the MAGE family of genes. It was identified that melanoma associated with antigens (MAAs). Because MAGE-1 is expressed on a significant proportion of human neoplasms of various hisological tyoes (melanoma, brain tumors of glial origin, neuroblastoma, non-small cell lung cancer, breast, gastric, colorectal, ovarian, renal cell carcinomas) and not on normal tissues, the encoded antigen may serve as a marker of early detection and target for cancer immunotherapy.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.